Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$20.06 - $28.66 $37,090 - $52,992
-1,849 Reduced 14.79%
10,651 $293,000
Q3 2023

Nov 14, 2023

SELL
$20.13 - $27.29 $88,632 - $120,157
-4,403 Reduced 26.05%
12,500 $295,000
Q2 2023

Aug 14, 2023

BUY
$18.33 - $27.18 $39,611 - $58,735
2,161 Added 14.66%
16,903 $445,000
Q1 2023

May 15, 2023

BUY
$14.25 - $20.5 $61,773 - $88,867
4,335 Added 41.65%
14,742 $271,000
Q4 2022

Feb 14, 2023

SELL
$12.8 - $23.66 $3,200 - $5,915
-250 Reduced 2.35%
10,407 $161,000
Q3 2022

Nov 14, 2022

SELL
$18.64 - $28.93 $25,033 - $38,852
-1,343 Reduced 11.19%
10,657 $213,000
Q2 2022

Aug 15, 2022

BUY
$13.98 - $29.25 $42,680 - $89,300
3,053 Added 34.12%
12,000 $272,000
Q1 2022

May 16, 2022

SELL
$23.58 - $30.91 $1,815 - $2,380
-77 Reduced 0.85%
8,947 $237,000
Q4 2021

Feb 14, 2022

SELL
$20.0 - $32.29 $220,180 - $355,480
-11,009 Reduced 54.95%
9,024 $287,000
Q3 2021

Nov 15, 2021

SELL
$16.48 - $27.23 $8,223 - $13,587
-499 Reduced 2.43%
20,033 $441,000
Q2 2021

Aug 16, 2021

BUY
$20.0 - $25.48 $14,700 - $18,727
735 Added 3.71%
20,532 $433,000
Q1 2021

May 14, 2021

BUY
$16.14 - $29.11 $3,340 - $6,025
207 Added 1.06%
19,797 $414,000
Q4 2020

Feb 16, 2021

SELL
$11.4 - $18.36 $15,572 - $25,079
-1,366 Reduced 6.52%
19,590 $343,000
Q3 2020

Nov 16, 2020

BUY
$10.57 - $16.0 $2,483 - $3,760
235 Added 1.13%
20,956 $251,000
Q2 2020

Aug 14, 2020

SELL
$10.5 - $17.36 $35,238 - $58,260
-3,356 Reduced 13.94%
20,721 $333,000
Q1 2020

May 15, 2020

SELL
$11.34 - $19.44 $10,466 - $17,943
-923 Reduced 3.69%
24,077 $291,000
Q4 2019

Feb 14, 2020

SELL
$14.08 - $18.5 $70,400 - $92,500
-5,000 Reduced 16.67%
25,000 $352,000
Q1 2019

May 15, 2019

BUY
$11.09 - $15.83 $55,450 - $79,150
5,000 Added 20.0%
30,000 $443,000
Q3 2018

Nov 14, 2018

BUY
$18.47 - $26.39 $461,750 - $659,750
25,000 New
25,000 $494,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Weiss Multi Strategy Advisers LLC Portfolio

Follow Weiss Multi Strategy Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.